KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Net Income towards Common Stockholders: 2017-2024

Historic Net Income towards Common Stockholders for Adaptive Biotechnologies (ADPT) over the last 8 years, with Dec 2024 value amounting to -$159.6 million.

  • Adaptive Biotechnologies' Net Income towards Common Stockholders rose 129.74% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year increase of 59.25%. This contributed to the annual value of -$159.6 million for FY2024, which is 29.16% up from last year.
  • Per Adaptive Biotechnologies' latest filing, its Net Income towards Common Stockholders stood at -$159.6 million for FY2024, which was up 29.16% from -$225.3 million recorded in FY2023.
  • Adaptive Biotechnologies' Net Income towards Common Stockholders' 5-year high stood at -$146.2 million during FY2020, with a 5-year trough of -$225.3 million in FY2023.
  • Over the past 3 years, Adaptive Biotechnologies' median Net Income towards Common Stockholders value was -$200.4 million (recorded in 2022), while the average stood at -$195.1 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 110.19% in 2020, then grew by 29.16% in 2024.
  • Adaptive Biotechnologies' Net Income towards Common Stockholders (Yearly) stood at -$146.2 million in 2020, then crashed by 41.75% to -$207.3 million in 2021, then increased by 3.33% to -$200.4 million in 2022, then dropped by 12.45% to -$225.3 million in 2023, then rose by 29.16% to -$159.6 million in 2024.